historical controls for open cholecystectomy, these placebotreated patients also did very well, as we now expect for laparoscopic cholecystectomy. Nonetheless, this simple, inexpensive, and apparently innocuous dose of preoperative steroid delivered just that much more benefit to patients. What is not clear is why it did.
To understand this, one can begin by considering the clinical efficacy of single-dose steroid therapy in elective major and minor surgery. There are several published trials available; however, variability in study populations, surgical procedures, protocols for steroid dosing, and endpoints of clinical outcome preclude any consensus. Holte and Kehlet, 7 also from this unit in Denmark, provide a comprehensive review of these trials and endorse the use of single-dose preoperative steroids. As an immune modulation strategy, such therapy does appear to shift the balance of inflammation in favor of antiinflammatory mediators in a variety of surgical procedures. Some aspects of cardiac 8 and pulmonary function 9 have been shown to improve, but usually in small studies of insufficient statistical power to detect reliable clinical differences. Trials aimed at evaluating side effects of preoperative single-dose steroids have also been inconclusive because of size and design. When considered together, however, it appears that this therapy is safe; it particularly does not increase complications one might expect, such as infections and impaired wound healing. It also appears that the timing of steroid administration is key (1-2 hours preoperative) if excess inflammatory activation and related postoperative morbidity is to be attenuated.
The incidence and severity of postoperative nausea and vomiting have been significantly decreased by preoperative single-dose steroid administration in several studies. 10 This can be explained by a central antiemetic mechanism involving endogenous prostaglandin and opioid production. Several studies suggest that pain is less as well; how this occurs is not known, though it may relate to reduced local tissue edema. These beneficial effects for nausea, vomiting, and pain are most reliably shown in studies of limited surgical trauma such as tonsillectomies, dental procedures, and now laparoscopic cholecystectomy. It has always been far more difficult to demonstrate any value from this therapy in major surgical procedures. For minor and minimally invasive procedures, one can expect that any positive impact on typical postoperative symptoms such as nausea, vomiting, and pain will directly translate to accelerated convalescence and return to normal activity.
Like any valuable study, the Bisgaard et al trial raises as many questions as it answers. Though generally well designed and executed, the trial still has certain peculiarities. When a statistical power analysis called for 39 patients/group to reveal effect of therapy, the authors evaluated 40/group. Will these results hold up with higher patient numbers? Also, some might question the exclusion criteria, especially those relating to infectious complications and even choledocholithiasis. Given any possibility that dexamethasone might promote infection or any unforeseen complication, larger numbers of patients may be better analyzed by intention-to-treat criteria. Certainly, the operative techniques and protocols for anesthesia and perioperative care as reported will differ from the nuances of others around the world. Only with substantially larger, multisite studies can these factors be tested and a recommendation for routine use be validated. If it is, issues of practicality, convenience, and logistics will arise next. We usually face issues of excess cost in dollars, equipment, and workforce, but not in this case. How will patients presenting for today's typical outpatient laparoscopic cholecystectomy reliably receive an intravenous steroid dose 90 minutes before their operation? It is not as easy as it may seem. Are there any oral or other substitutes that can achieve the same desired clinical efficacy? Have they been evaluated?
In summary, we have an opportunity to enhance further the immediate benefits of minimally invasive surgery. This simple therapy warrants broader evaluation across many laparoscopic procedures. The capacity for single-dose steroid therapy to turn down the volume of a systemic stress and immune response 11 may only become clinically evident when the volume is not too high to begin with. This is an intuitive but key insight as to why these patients had measurably improved clinical outcomes after elective minimally invasive surgery.
